Double maintains 1 strategies that include FDMT - 4D Molecular Therapeutics, Inc.
Yahoo
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit
Yahoo
EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC Capital Markets 2025 Ophthalmology Conference being held virtually on April 3-4, 2025. Members of the m
Finnhub
Barclays Global Healthcare Conference 2025 Corporate Presentation March 2025 © 2025 4D...
Yahoo
EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 Phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degenera
Yahoo
RBC Capital lowered the firm’s price target on 4D Molecular (FDMT) to $35 from $39 but keeps an Outperform rating on the shares after its Q4 results. The company’s first of two wet AMD – wAMD – pivotal studies is on track to initiate this month, with 4D also anticipating the second study to launch in Q3, the analyst tells investors in a research note. 4D Molecular has an ideal benefit/risk profile for wAMD / DME, or diabetic macular edema, and the firm also likes that strategic focus has been sh
Yahoo
4D Molecular Therapeutics ( NASDAQ:FDMT ) Full Year 2024 Results Key Financial Results Net loss: US$160.9m (loss...
Current Value
$3.121 Year Return
Current Value
$3.121 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
JMST | -0.14% | $3.54B | 0.18% |
CLOI | -0.18% | $1.01B | 0.4% |
OIH | 0.25% | $1.22B | 0.35% |
VDC | -0.35% | $7.46B | 0.09% |
CMDY | 0.38% | $313.96M | 0.28% |
CLOA | -0.47% | $783.46M | 0.2% |
FSTA | -0.47% | $1.30B | 0.084% |
USFR | -0.48% | $18.53B | 0.15% |
LVHD | 0.59% | $547.23M | 0.27% |
STPZ | 0.62% | $427.83M | 0.2% |
ICLO | 0.78% | $354.74M | 0.2% |
JUCY | -0.92% | $306.51M | 0.6% |
TBIL | -0.97% | $5.39B | 0.15% |
UNG | -1.02% | $397.59M | 1.06% |
ULST | 1.05% | $585.14M | 0.2% |
CCOR | -1.07% | $64.12M | 1.18% |
BCI | 1.14% | $1.45B | 0.26% |
IEZ | 1.16% | $154.35M | 0.4% |
GCC | 1.27% | $149.77M | 0.55% |
FCG | -1.36% | $399.21M | 0.6% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -27.14% | $416.76M | 1.43% |
VIXY | -20.09% | $195.31M | 0.85% |
DBO | -16.96% | $202.41M | 0.77% |
DBE | -16.95% | $55.52M | 0.77% |
USO | -16.81% | $972.70M | 0.6% |
BNO | -16.30% | $99.25M | 1% |
USL | -14.97% | $47.77M | 0.85% |
OILK | -14.62% | $67.85M | 0.69% |
TAIL | -13.28% | $87.65M | 0.59% |
UGA | -12.92% | $87.23M | 0.97% |
USDU | -12.31% | $206.96M | 0.5% |
COMT | -11.23% | $684.20M | 0.48% |
UUP | -10.55% | $325.79M | 0.77% |
PDBC | -10.49% | $4.89B | 0.59% |
FTXG | -10.12% | $26.06M | 0.6% |
KCCA | -9.72% | $108.04M | 0.87% |
IYK | -9.52% | $1.53B | 0.4% |
TPMN | -9.38% | $33.32M | 0.65% |
DRLL | -9.16% | $304.11M | 0.41% |
DBC | -8.91% | $1.36B | 0.87% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ZYXI | -<0.01% | $77.87M | -80.05% | 0.00% |
DK | -0.03% | $957.69M | -51.88% | 7.52% |
OCX | 0.03% | $84.37M | +0.34% | 0.00% |
CCI | 0.03% | $45.20B | +1.61% | 5.85% |
BF.A | 0.04% | $16.02B | -35.88% | 2.70% |
SXC | -0.05% | $779.41M | -18.37% | 5.24% |
PARR | -0.06% | $814.72M | -61.77% | 0.00% |
VRSK | -0.06% | $42.04B | +29.74% | 0.53% |
HE | 0.07% | $1.88B | -1.18% | 0.00% |
ABBV | 0.07% | $362.98B | +15.71% | 3.07% |
BOX | -0.07% | $4.53B | +13.12% | 0.00% |
ENFN | 0.08% | $1.06B | +19.53% | 0.00% |
WMK | 0.09% | $2.13B | +26.32% | 1.73% |
MOS | -0.09% | $8.39B | -18.68% | 3.27% |
SPRU | -0.09% | $38.33M | -41.76% | 0.00% |
CVE | -0.10% | $25.60B | -32.78% | 3.91% |
CRC | 0.11% | $4.14B | -15.01% | 3.59% |
GD | -0.17% | $74.63B | -5.37% | 2.09% |
EGO | -0.17% | $3.68B | +19.31% | 0.00% |
PRGS | 0.19% | $2.54B | +14.30% | 0.61% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -18.64% | $23.50B | +25.53% | 1.05% |
GIS | -17.77% | $32.41B | -14.20% | 3.90% |
VZ | -15.88% | $188.34B | +4.44% | 5.84% |
PRPO | -15.77% | $8.36M | -11.96% | 0.00% |
CPB | -14.66% | $11.75B | -8.27% | 3.73% |
HRL | -13.66% | $16.84B | -11.83% | 3.62% |
NSP | -12.81% | $3.32B | -16.89% | 2.82% |
KO | -12.79% | $306.97B | +19.22% | 2.66% |
CVX | -12.75% | $291.28B | +3.76% | 4.19% |
MUR | -12.72% | $4.26B | -39.61% | 4.75% |
NOC | -12.46% | $74.14B | +12.07% | 1.60% |
PEP | -12.16% | $204.52B | -12.12% | 3.52% |
K | -12.04% | $28.46B | +45.70% | 2.75% |
OXY | -12.03% | $46.36B | -27.15% | 2.00% |
LITB | -11.88% | $41.93M | -46.48% | 0.00% |
PGR | -11.79% | $164.86B | +33.43% | 1.71% |
SJM | -11.63% | $12.61B | -0.90% | 3.59% |
HES | -11.61% | $49.33B | +2.46% | 1.30% |
MO | -11.61% | $96.57B | +35.61% | 6.83% |
QXO | -11.57% | $6.03B | -83.01% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 42.91% | $4.76B | 0.35% |
GNOM | 41.55% | $47.13M | 0.5% |
ARKG | 38.54% | $936.86M | 0.75% |
IWC | 36.76% | $797.08M | 0.6% |
HDRO | 36.47% | $164.26M | 0.3% |
PTH | 35.83% | $107.91M | 0.6% |
IBB | 35.69% | $5.61B | 0.45% |
PBW | 34.34% | $213.72M | 0.65% |
IWO | 33.15% | $10.72B | 0.24% |
CPRJ | 32.40% | $48.38M | 0.69% |
CWB | 31.91% | $3.78B | 0.4% |
KOMP | 31.76% | $1.95B | 0.2% |
ICLN | 30.98% | $1.32B | 0.41% |
PFUT | 30.69% | $321.92M | 0.65% |
BSJP | 30.54% | $991.97M | 0.43% |
VTWO | 30.46% | $10.92B | 0.07% |
IWM | 30.40% | $62.65B | 0.19% |
ICVT | 30.36% | $2.54B | 0.2% |
KAPR | 30.21% | $144.85M | 0.79% |
BBH | 30.18% | $358.88M | 0.35% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STOK | 40.87% | $356.91M | -48.50% | 0.00% |
IMNM | 39.01% | $583.44M | -68.94% | 0.00% |
RGNX | 36.82% | $353.11M | -65.19% | 0.00% |
VTYX | 36.76% | $75.40M | -79.54% | 0.00% |
KRO | 36.66% | $853.57M | -38.93% | 4.94% |
IDYA | 36.14% | $1.43B | -61.21% | 0.00% |
NNOX | 36.04% | $287.24M | -54.79% | 0.00% |
PLRX | 35.92% | $86.34M | -90.23% | 0.00% |
DNLI | 35.56% | $2.00B | -29.07% | 0.00% |
RCKT | 35.49% | $671.77M | -75.23% | 0.00% |
KYMR | 35.42% | $1.71B | -29.01% | 0.00% |
CMPS | 35.29% | $211.83M | -68.14% | 0.00% |
SUNS | 35.25% | $146.83M | -3.19% | 8.82% |
BEAM | 34.21% | $1.85B | -37.74% | 0.00% |
NTLA | 33.90% | $755.67M | -70.78% | 0.00% |
WHWK | 33.81% | $79.53M | -22.37% | 0.00% |
CRSP | 33.65% | $2.93B | -47.07% | 0.00% |
YMAB | 33.63% | $217.05M | -66.71% | 0.00% |
FATE | 33.11% | $88.24M | -89.02% | 0.00% |
APGE | 32.91% | $2.25B | -36.95% | 0.00% |